FREMONT, Calif., Oct. 2, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today that it has completed a private placement to accredited investors of $15,037,500 of units consisting of shares of common stock, shares of Series 1 convertible preferred stock and warrants to purchase shares of common stock.
As previously announced, at the initial closing of the offering on August 27, 2013, the Company sold $13,668,500 of units for net proceeds of approximately $12,300,000. At a subsequent closing on September 30, 2013, the Company sold an additional $1,369,000 of units for net proceeds of approximately $1,200,000. In the private placement, the Company issued a total of 5,893,750 shares of common stock, 646 shares of Series 1 preferred stock (with a $0.001 per share liquidation preference and convertible into a total of 1,625,000 shares of Common Stock) and 3,759,379 five-year warrants with a $2.60 exercise price. For additional details regarding the private placement, please see the current report on Form 8-K filed by the Company on August 28, 2013.
National Securities Corporation acted as sole placement agent in connection with the Offering and received compensation of approximately $1,300,000 cash and warrants to purchase 35.88 units at an initial exercise price of $50,000 per unit.
As previously reported, immediately prior to the initial closing of the private placement, the Company completed a restructuring transaction pursuant to which the Company exchanged shares of Series A-1 preferred stock with a liquidation preference of approximately $17.1 million, convertible notes with a principal amount of approximately $17.1 million and warrants exercisable for 565,180 shares of common stock for 2,987 shares of Series 1 preferred stock (with a $0.001 per share liquidation preference and convertible into a total of 7,513,372 shares of Common Stock), 1,067,317 shares of common sto
|SOURCE WaferGen Bio-systems, Inc.|
Copyright©2012 PR Newswire.
All rights reserved